ACP
CNST

Acuta Capital Partners’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Acuta Capital Partners’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-139,464
Closed -$4.38M – 51
2020
Q1 		$4.38M Sell
139,464
-58,036
-29% -$2.02M 2.12% 19
2019
Q4 		$9.3M Buy
+197,500
New +$5.7M 2.3% 14

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMV
Venrock Management V Palo Alto, California $719M AUM
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Acuta Capital Partners's CNST Position: Q2 2020 in Review

Acuta Capital Partners sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2020, closing a stake of 139,464 shares — an estimated $4.38M sold.

Acuta Capital Partners first reported a position in CNST in Q4 2019 and held it in 2 quarters. The position peaked at $9.3M in Q4 2019. 132 funds tracked by Wall St. Rank hold CNST as of Q2 2020.

  • Acuta Capital Partners reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 139,464 Constellation Pharmaceuticals, Inc. shares in Q2 2020, an estimated $4.38M.
  • Acuta Capital Partners first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • Acuta Capital Partners's Constellation Pharmaceuticals, Inc. position peaked at $9.3M in Q4 2019.
  • 132 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2020.

Based on Acuta Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.